UBS Group’s CoLucid Pharmaceuticals, Inc. CLCD Stock Holding History

UBS Group’s Portfolio CLCD Stock Details CLCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-522	Closed	-$19K	–	8357
2016 Q4	$19K	Buy	522 +322	+161%	+$11.4K	﹤0.01%	6566
2016 Q3	$8K	Buy	+200	New	+$2.96K	﹤0.01%	6954
2015 Q4	–	Sell	-1,627	Closed	-$6K	–	8778
2015 Q3	$6K	Buy	1,627 +348	+27%	+$2.57K	﹤0.01%	7653
2015 Q2	$11K	Buy	+1,279	New	+$11K	﹤0.01%	7429

Other funds holding CLCD

FPF

FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

UBS Group's CLCD Position: Q1 2017 in Review

UBS Group sold out of CoLucid Pharmaceuticals, Inc. (CLCD) in Q1 2017, closing a stake of 522 shares — an estimated $19K sold.

UBS Group first reported a position in CLCD in Q2 2015 and held it in 4 quarters. The position peaked at $19K in Q4 2016. 1 fund tracked by Wall St. Rank holds CLCD as of Q1 2017.

UBS Group reported no remaining CoLucid Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
UBS Group sold 522 CoLucid Pharmaceuticals, Inc. shares in Q1 2017, an estimated $19K.
UBS Group first reported a position in CoLucid Pharmaceuticals, Inc. in Q2 2015 and held it in 4 quarters.
UBS Group's CoLucid Pharmaceuticals, Inc. position peaked at $19K in Q4 2016.
1 fund tracked by Wall St. Rank held CoLucid Pharmaceuticals, Inc. as of Q1 2017.

Based on UBS Group's 13F filing for Q1 2017, filed 12 May 2017.